The authors, led by Shenghao Man, Xuebo Liu, Di Wang, and Qi Yu, synthesize existing research on how aberrant condensate formation reshapes gene regulatory networks in glioma cells.
According to the review, dysregulated expression and post-translational modifications of phase-separating proteins can promote oncogenic transcription at super-enhancers, dense clusters of regulatory elements that drive tumor-promoting gene expression programs. The authors also describe how condensates such as stress granules and P-bodies alter post-transcriptional mRNA metabolism, potentially changing which proteins glioma cells produce and how they respond to treatment.
The review identifies several established and proposed drivers of pathological condensation. These include intrinsically disordered protein regions and multivalent interactions involving the transcriptional co-activators YAP/TAZ, the stemness factor SOX2, and the fatty acid-binding protein FABP5. It also highlights the condensate-associated long noncoding RNAs NEAT1 and MALAT1, as well as crosstalk among phosphorylation, methylation, acetylation, and ubiquitination, chemical modifications that collectively modulate the formation and dynamics of condensates within tumor cells.
Beyond transcriptional control, the authors propose that phase separation may integrate major cancer signaling pathways, including Wnt/β-catenin, MAPK/ERK, PI3K-AKT-mTOR, and cGAS-STING, into signaling hubs. Such hubs, they suggest, could sustain glioma stem cell phenotypes and support microenvironmental adaptation, helping tumors survive hostile conditions and therapeutic pressure.
A substantial portion of the review is devoted to emerging therapeutic strategies that target pathological condensates. These include small-molecule inhibitors designed to disrupt harmful condensate formation, interventions directed at specific post-translational modifications, and nanocarrier systems that exploit condensate properties for selective drug delivery to tumor cells.
The authors frame the work as a conceptual framework for understanding tumor heterogeneity and treatment failure in glioblastoma, while identifying potential therapeutic vulnerabilities that future research could pursue. As a review article, it synthesizes and interprets existing literature rather than presenting new experimental data, and many of the mechanisms it describes, particularly the proposed signaling hubs and therapeutic approaches, remain hypotheses or early-stage findings that will require direct experimental validation in glioma models and, ultimately, clinical studies.
Subject of Research: The role of liquid-liquid phase separation and biomolecular condensates in glioblastoma progression and therapy resistance
Article Title: Pathological condensates in glioblastoma: phase separation drives progression and resistance
Article References: Man, S., Liu, X., Wang, D., & Yu, Q. (2026). Pathological condensates in glioblastoma: phase separation drives progression and resistance. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-026-02469-7
Image Credits: AI Generated
DOI: 10.1186/s40478-026-02469-7
Keywords: glioblastoma, liquid-liquid phase separation, biomolecular condensates, super-enhancers, stress granules, NEAT1, MALAT1, YAP/TAZ, SOX2, post-translational modifications, therapy resistance, glioma stem cells
News Source: Kristina Jarvis. (October 28, 2026). Phase-Separating Condensates Emerge as Drivers of Glioblastoma Progression and Drug Resistance. Scienmag.
